Caffeine attenuates lipopolysaccharide-induced neuroinflammation

Neuroscience Letters

Volumn 480, Issue 2, 2010, Pages 97-100

  Brothers, Holly M ^a   Marchalant, Yannick ^b   Wenk, Gary L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Mediterranée University   (France)

Author keywords

Aging; Glutamate; Hippocampus; Microglia; Neuroinflammation; Rats

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; CAFFEINE; GLUTAMIC ACID; LIPOPOLYSACCHARIDE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENCEPHALITIS; HIPPOCAMPUS; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; AGING; ANIMAL; CHRONIC DISEASE; DRUG EFFECTS; FISCHER 344 RAT; INFLAMMATION; PATHOLOGY;

AGING; ANIMALS; CAFFEINE; CHRONIC DISEASE; HIPPOCAMPUS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; RATS; RATS, INBRED F344; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS;

EID: 77954541590     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.013     Document Type: Article

References (41)

1. Ascherio A., Zhang S.M.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50:56-63.
2. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., Vescovi A., Bagetta G., Kollias G., Meldolesi J., Volterra A. CXCR4-activated astrocyte glutamate release via TNF alpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 2001, 4:702-710.
3. Bibbiani F., Oh J., Petzer J., Castagnoli N.J., Chen J., Schwarzschild M., Chase T. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 2003, 184:285-294.
4. Blasko I., Marx F., Steiner E. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
5. Carta A.R., Kachroo A., Schintu N., Xu K., Schwarzschild M.A., Wardas J., Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
6. Ciruela F., Casado V., Rodrigues R.J., Lujan R., Burgueno J., Canals M., Borycz J., Rebola N., Goldberg S.R., Mallol J., Cortex A., Canela E.L., Lopez-Gimenez J.F., Milligan G., Lluis C., Cunha R.A., Ferre S., Franco R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A(1)-A(2A) receptor heteromers. J. Neurosci. 2006, 26:2080-2087.
7. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20:95-116.
8. Dai S.-S., Zhou Y.-G., Li W., An J.-H., Li P., Yang N., Chen X.-Y., Xiong R.-P., Liu P., Zhao Y., Shen H.-Y., Zhu P.-F., Chen J.-F. Local glutamate levels dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J. Neurosci. 2010, 30:5802-5810.
9. Dare E., Schulte G., Karovic O., Hammarberg C., Fredholm B.B. Modulation of glial cell functions by adenosine receptors. Physiol. Behav. 2007, 92:15-20.
10. de Mendoca A., Sebastiao A.M., Ribeiro J.A. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor. Neuroreport 1995, 6:1097-1100.
11. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Ann. Rev. Neurosci. 2001, 24:31-55.
12. Eskelinen M., Ngandu T., Tuomilehto J., Soininen H., Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J. Alzheimers Dis. 2009, 16:85-91.
13. Ferre S., Ciruela F., Borycz J., Solinas M., Quarta D., Antoniou K., Quiroz C., Justinova Z., Lluis C., Franco R., Goldberg S.R. Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front. Biosci. 2008, 13:2391-2399.
14. Fredholm B.B., Battig K., Holmen J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51:84-133.
15. Hauss-Wegrzyniak B., Dobrzanski P., Stoehr J.D., Wenk G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 1998, 780:294-303.
16. Hauss-Wegrzyniak B., Vraniak P., Wenk G.L. The effects of a novel NSAID upon chronic neuroinflammation are age dependent. Neurobiol. Aging 1999, 20:305-313.
17. Hasko G., Pacher P., Vizi E.S., Illes P. Adenosine receptor signaling in the brain immune system. Trends Pharmacol. Sci. 2005, 26:511-516.
18. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. NY Acad. Sci. 2003, 991:214-228.
19. Hofmann K.W., Schuh A.F., Saute J., Townsend R., Fricke D., Leke R., Souza D.O., Portela L.V., Chaves M.L., Rieder C.R. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem. Res. 2009, 34:1401-1404.
20. Jacobson K.A., von Lubitz D.K.J.E., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 1996, 17:108-113.
21. Johansson B., Ahlberg S., Vanderploeg I., Brene S., Lindefors N., Persson H., Fredholm B.B. Effect of long-term caffeine treatment on A(1) and A(2) adenosine receptor-binding and on messenger-RNA levels in rat-brain. Naunyn Schmiedebergs Arch. Pharm. 1993, 347:407-414.
22. Kalda A., Yu L., Oztas E., Chen J.F. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J. Neurol. Sci. 2006, 248:9-15.
23. Koizumi S., Fujishita K., Tsuda M., Inoue K. Neurone-to-astrocyte communication by endogenous ATP in mixed culture of rat hippocampal neurons and astrocytes. Drug Dev. Res. 2003, 59:88-94.
24. Li Y., Cao Y.P. Changes in intracellular calcium in brain cells of aged rats. Neural Regener. Res. 2008, 3:1026-1029.
25. Lopes L.V., Cunha R.A., Kull B., Fredholm B.B., Ribeiro J.A. Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience 2002, 112:319-329.
26. Lopes L.V., Cunha R.A., Ribeiro J.A. Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 1999, 82:3196-3203.
27. Lupica C.R., Berman R.F., Jarvis M.F. Chronic theophylline treatment increases adenosine-A1, but not adenosine-A2, receptor-binding in the rat-brain - an autoradiographic study. Synapse 1991, 9:95-102.
28. Maia L., de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 2002, 9:377-382.
29. Marchalant Y., Rosi S., Wenk G.L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of Alzheimer's disease. Neuroscience 2007, 144:1516-1522.
30. Marchi M., Raiteri L., Risso F., Vallarino A., Bonfanti A., Monopoli A., Ongini E., Raiteri M. Effects of adenosine A(1) and A(2A) receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol. 2002, 136:434-440.
31. Pintor A., Galluzzo M., Grieco R., Pezzola A., Reggio R., Popoli P. Adenosine A(2A) receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J. Neurochem. 2004, 89:152-156.
32. Rebola N., Lujan R., Cunha R.A., Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008, 57:121-134.
33. Rebola N., Rodrigues R.J., Lopes L.V., Richardson P.J., Oliveira C.R., Cunha R.A. Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localizd in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 2005, 133:79-83.
34. 2B receptors. J. Neurochem. 2003, 86:220-227.
35. Rosi S., Ramirez-Amaya V., Vazdarjanova A., Esperanza E., Larkin P., Fike J.R., Wenk G.L., Barnes C.A. Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. Brain 2009, 132:2464-2486.
36. Rosi S., Ramirez-Amaya V., Vazdarjanova A., Worley P.F., Barnes C.A., Wenk G.L. Neuroinflammation alters selective patterns of behaviorally induced Arc expression in the hippocampus. J. Neurosci. 2005, 25:723-731.
37. Rosi S., Vazdarjanova A., Ramirez-Amaya V., Worley P.F., Barnes C.A., Wenk G.L. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142:1303-1315.
38. Rothwell N.J., Allan S., Toulmond S. The role of interleukin-1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J. Clin. Invest. 1997, 100:2648-2652.
39. Thibault O., Gant J.C., Landfield P.W. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 2007, 6:307-317.
40. van Gelder B., Buijsse B., Tijhuis M., Kalmijn S., Giampaoli S., Nissinen A., Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur. J. Clin. Nutr. 2007, 61:226-232.
41. Yaar R., Jones M.R., Chen J.F., Ravid K. Animal models for the study of adenosine receptor function. J. Cell. Physiol. 2005, 202:9-20.